Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2018.02.020
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2018
Authors
Publisher
Elsevier BV